Liu, Cheng
Hu, Shihui
Xu, Xiaoping
Zhang, Yongping
Wang, Biyun
Song, Shaoli
Yang, Zhongyi http://orcid.org/0000-0001-6195-9942
Clinical trials referenced in this document:
Documents that mention this clinical trial
Evaluation of tumour heterogeneity by 18F-fluoroestradiol PET as a predictive measure in breast cancer patients receiving palbociclib combined with endocrine treatment
https://doi.org/10.1186/s13058-022-01555-7
Funding for this research was provided by:
National Natural Science Foundation of China (81874114)
Shanghai Sailing Program (20YF1408500)
Shanghai Committee of Science and Technology Fund (19ZR1411300)
Shanghai Municipal Health Commission (202040269)
Science and Technology Development Fund of Shanghai Pudong New Area (PKJ2020-Y54)
Article History
Received: 3 November 2021
Accepted: 16 August 2022
First Online: 26 August 2022
Declarations
:
: The study has been approved by the Fudan University Shanghai Cancer Center Ethic Committee and Institutional Review Boards for clinical investigation, and the need for informed consent was waived as it’s a retrospective study.
: Not applicable.
: The authors declare that they have no competing interest.